Results 161 to 170 of about 5,418,578 (179)
Some of the next articles are maybe not open access.
Vimseltinib (Romvimza) for Tenosynovial Giant Cell Tumor
The Medical Letter on Drugs and TherapeuticsVimseltinib (Romvimza – Deciphera), an oral kinase inhibitor, has been approved by the FDA for treatment of symptomatic tenosynovial giant cell tumor in adults for whom surgical resection would cause worsening functional limitation or severe morbidity. The kinase inhibitor pexidartinib (Turalio) was approved for a similar indication in 2019.
openaire +2 more sources
An evaluation of vimseltinib for treatment of tenosynovial giant cell tumors
Expert Review of Anticancer TherapyTenosynovial giant cell tumor (TGCT) is a rare soft tissue neoplasm with aggressive local growth. The disease is driven by excessive CSF1 expression in tumor cells, leading to increased recruitment of monocytes and macrophages, cytokine production, and tumor development. Targeted therapy against CSF1R is an effective treatment approach for unresectable,
Katarzyna, Kisielewska, Piotr, Rutkowski
openaire +2 more sources
Tenosynovial Giant Cell Tumor of the Finger
2023null Joseph E. Judge, MD +2 more
openaire +1 more source
Pexidartinib for the treatment of adult symptomatic patients with tenosynovial giant cell tumors
Expert Review of Clinical Pharmacology, 2020Silvia Stacchiotti +2 more
exaly
MRI Prediction Model for Tenosynovial Giant Cell Tumor with Risk of Diffuse-type
Academic Radiology, 2023Seul Ki Lee
exaly
Detection of CSF1 rearrangements deleting the 3′ UTR in tenosynovial giant cell tumors
Genes Chromosomes and Cancer, 2020Brendan C Dickson +2 more
exaly